Evidence map›Paper›PMID 39723239›Full record

ReviewFrontiers in cell and developmental biology2024

Multi-omics in exploring the pathophysiology of diabetic retinopathy.

Xinlu Li, XiaoJing Dong, Wen Zhang, Zhizhou Shi, Zhongjian Liu, Yalian Sa, Li Li, Ninghua Ni, Yan Mei

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Illuminating diabetesWorld journal of diabetes · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinlu LiFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China.
XiaoJing DongDepartment of Ophthalmology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Wen ZhangMedical School, Kunming University of Science and Technology, Kunming, China.
Zhizhou ShiFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China.
Zhongjian LiuInstitute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Yalian SaInstitute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Li LiInstitute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
Ninghua NiDepartment of Ophthalmology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Yan MeiDepartment of Ophthalmology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy (DR) is a leading global cause of vision impairment, with its prevalence increasing alongside the rising rates of diabetes mellitus (DM). Despite the retina's complex structure, the underlying pathology of DR remains incompletely understood. Single-cell RNA sequencing (scRNA-seq) and recent advancements in multi-omics analyses have revolutionized molecular profiling, enabling high-throughput analysis and comprehensive characterization of complex biological systems. This review highlights the significant contributions of scRNA-seq, in conjunction with other multi-omics technologies, to DR research. Integrated scRNA-seq and transcriptomic analyses have revealed novel insights into DR pathogenesis, including alternative transcription start site events, fluctuations in cell populations, altered gene expression profiles, and critical signaling pathways within retinal cells. Furthermore, by integrating scRNA-seq with genetic association studies and multi-omics analyses, researchers have identified novel biomarkers, susceptibility genes, and potential therapeutic targets for DR, emphasizing the importance of specific retinal cell types in disease progression. The integration of scRNA-seq with metabolomics has also been instrumental in identifying specific metabolites and dysregulated pathways associated with DR. It is highly conceivable that the continued synergy between scRNA-seq and other multi-omics approaches will accelerate the discovery of underlying mechanisms and the development of novel therapeutic interventions for DR.

Indexed as

diabetic retinopathy (DR)genomicslipidomicmetabolomicmulti-omicssingle-cell RNA sequencing(scRNA-seq)transcriptomics

Identifiers

PMID39723239
PMCPMC11668801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.